Vaxcyte Valuation
| PCVX Stock | USD 36.21 1.16 3.10% |
At this time, the company appears to be undervalued. Vaxcyte has a current Real Value of $56.82 per share. The regular price of the company is $36.21. Our model measures the value of Vaxcyte from inspecting the company fundamentals such as Shares Owned By Institutions of 99.32 %, return on equity of -0.2, and Shares Outstanding of 129 M as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Vaxcyte's price fluctuation is very steady at this time. Calculation of the real value of Vaxcyte is based on 3 months time horizon. Increasing Vaxcyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Vaxcyte is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vaxcyte Stock. However, Vaxcyte's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 36.21 | Real 56.82 | Hype 35.96 | Naive 39.89 |
The intrinsic value of Vaxcyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaxcyte's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaxcyte helps investors to forecast how Vaxcyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaxcyte more accurately as focusing exclusively on Vaxcyte's fundamentals will not take into account other important factors: Vaxcyte Total Value Analysis
Vaxcyte is at this time anticipated to have valuation of 3.09 B with market capitalization of 4.67 B, debt of 71.11 M, and cash on hands of 354.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Vaxcyte fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.09 B | 4.67 B | 71.11 M | 354.5 M |
Vaxcyte Asset Utilization
One of the ways to look at asset utilization of Vaxcyte is to check how much profit was generated for every dollar of assets it reports. Vaxcyte has a negative utilization of assets of -0.15 %, losing $0.001453 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Vaxcyte shows how discouraging it operates for each dollar spent on its assets.Vaxcyte Ownership Allocation
The majority of Vaxcyte outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vaxcyte to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vaxcyte. Please pay attention to any change in the institutional holdings of Vaxcyte as this could imply that something significant has changed or is about to change at the company.Vaxcyte Profitability Analysis
Net Loss for the year was (463.93 M) with loss before overhead, payroll, taxes, and interest of (75 M).About Vaxcyte Valuation
Our relative valuation model uses a comparative analysis of Vaxcyte. We calculate exposure to Vaxcyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaxcyte's related companies.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
Vaxcyte Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 122 M |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.